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Available online 22 November 2016AbstractEstrogen receptor (ER) antagonists such as tamoxifen (Tam) have been used successfully to treat ERþ breast cancers for more than 30 years.
Unfortunately, long term use of Tam can result in resistance. Tam resistance is associated with the activation of growth factor signaling pathways
that promote cell proliferation and survival. The mitogen-activated protein kinase (MAPK), is up-regulated in Tam resistant (Tam-R) cells.
Previous studies have reported that the flavanone, naringenin (Nar) can inhibit cell proliferation and induce apoptosis in ERþ breast cancer cells.
Furthermore, Nar has been shown to inhibit the MAPK signaling pathways in MCF-7 cells. In this report we investigated whether inhibition of
MAPK alone is mediating the effects of Nar on cell proliferation and viability. These studies will determine the mechanism of action of Nar.
Tam-R MCF-7 breast cancer cells were treated with Nar or U0126, a MAPK kinase inhibitor. Our studies show that while both U0126 and Nar
impaired cell proliferation and viability the combination of U0126 and Nar resulted in greater inhibition of cell viability than either compound
alone. It has been previously reported that Nar can bind the ER. Our lab has also shown that Nar localizes ERa to a peri-nuclear region of the
cell. Confocal microscopy revealed that in U0126 treated cells ERa displayed an even distribution across the cytoplasm as seen in untreated
Tam-R cells. These studies suggest that MAPK is not the only target of Nar.
© 2016 The Authors. Published by Elsevier B.V. on behalf of Socie´te´ Franc¸aise de Biochimie et Biologie Mole´culaire (SFBBM). This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Since the majority of breast cancers are dependent on es-
trogen stimulated growth, anti-estrogen treatments such as
tamoxifen (Tam) are successful [1]. Tam has been shown to
be a safe and effective treatment for advanced breast cancer
[2,3]. Tam binds the estrogen receptor (ER), and inhibits the
expression of estrogen-regulated genes, thus impairing pro-
liferation and viability [2,4]. Unfortunately, the therapeutic
benefits of Tam are limited by acquired resistance [5,6].
Multiple signaling pathways, such as the MAPK pathway
can activate the ER. Thus, Tam-resistant (Tam-R) cells have
a heightened sensitivity to both growth factor and estradiol* Corresponding author. Department of Biology, University of North
Carolina e Greensboro, 312 Eberhart Bldg., Greensboro, NC 27412, USA.
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article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nactivation of MAPK [7e9]. The upregulation of MAPK
signaling has been reported as a primary pathway by which
ERa is activated in Tam-R cells. Therefore, inhibition of
MAPK may be a likely means of inhibiting cell growth and
survival of Tam-R breast cancer cells.
The ER is a hormone receptor and transcription factor. The
ER is localized primarily within the nucleus, however it is
present in the cytoplasm and at the membrane [10,11]. Acti-
vation of the ER can be achieved through ligand-dependent or
independent pathways. Ligand-dependent activation of the ER
is mediated by estrogen binding. Following estrogen binding,
the ER forms homodimers that translocates to the nucleus and
bind to estrogen-responsive element of target genes [12,13].
In contrast, the ER can also induce a non-genomic rapid
response [1,11,12,14]. ERa can bind to the plasma membrane
where the rapid, extra-nuclear response is initiated [11,14].
Once bound by estrogen, the ER is released from thenc¸aise de Biochimie et Biologie Mole´culaire (SFBBM). This is an open access
c-nd/4.0/).
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protein kinase (MAPK) and phosphoinositide 3-kinase
(PI3K) pathways, both of which are pro-survival and growth
[11,14,15]. ERa can also directly activate the epidermal
growth factor receptor (EGFR), causing activation of the
MAPK and PI3K pathways [15,16].
Ligand-independent activation of the ER is a result of
phosphorylation of multiple serine and tyrosine residues
[1,10,13]. Growth factor receptors can activate the ER through
several signaling pathways including the MAPK (Ras-Raf-
MEK-ERK1/2) and PI3K (AKT) pathways [6,10,16]. ERK
(Extracellular signal-regulated kinases) 1 and 2 and AKT
(protein kinase B) phosphorylate serine 118 of the ER resulting
in its activation [10,16]. Ligand-independent activation of the
ER has increased the need for treatments that target not only
the ER but also these signaling pathways to block cell growth.
ERþ Tam-R cell lines are reported to have constitutive
activation of both the PI3K/AKTand MAPK pathways [15]. As
mentioned above, this constitutive activation of these pathways
results in activation of the ER independent of estrogen allowing
growth to occur. The MAPK cascades are important regulatory
pathways for cell proliferation, survival, and differentiation
[17,18]. Various kinases in the MAPK pathway are often
mutated in cancers, including Ras (the most frequently mutated
oncogene) [18]. Abnormal activation of the MAPK pathway
can result in alterations of proliferation as well as survival and
migration, which is often associated with therapy resistance
[19,20]. Thus the identification of kinase inhibitors is critical to
impair Tam-R cell proliferation and survival.
Flavonoids have been implicated in the reduction and
protection against the development of endocrine tumors by
binding the ER in individuals consuming a diet rich in flavo-
noids [11]. Naringenin (Nar), a grapefruit flavanone has been
reported to induce apoptosis in different cancer cell lines
containing ERa or ERb [11,14]. The exact mechanism of
reduced proliferation and growth arrest of the cells is not
understood. Our previous findings suggest that Nar affects the
MAPK signaling pathway which can result in decreased pro-
liferation and cell survival [14]. It has also been reported that
Nar induces apoptosis in various cancer cells including MCF-7
breast cancer cells [14,21,22]. We have shown that the addi-
tion of Nar impaired proliferation of Tam-R cells. Further-
more, Tam-R cells exhibited an up-regulation of the MAPK
pathway which was reversed by Nar. We also found that in
Tam-R cells ERa exhibited a different localization pattern
compared to the tamoxifen sensitive MCF-7 cells. ERa is
distributed primarily in the nucleus of MCF-7 cells. Tam-R
cells have an increased level of ERa in the cytoplasm that is
evenly distributed. However, upon Nar treatment ERa local-
ized to a peri-nuclear region of Tam-R cells. These known
effects of naringenin can be used as markers to identify crucial
targets and components of naringenin signaling.
The goal of this study was to identify the targets of Nar and
to gain a greater understanding of the mechanism(s) involved
in Tam-R MCF-7 cell proliferation and viability. Here we
wanted to determine if inhibition of MAPK alone is mediating
all the effects of Nar on cell proliferation and viability. Ourstudies show that while both Nar and inhibition of MAPK
impaired viability, the combination resulted in greater inhibi-
tion than either compound alone. Furthermore, inhibition of
MAPK is not involved in the peri-nuclear localization of ERa
seen in Nar treated Tam-R cells.
2. Materials and methods2.1. MaterialsMCF-7 ERþ breast cancer cells (HTB-22) were purchased
from ATCC. Dulbecco's Modified Eagle Medium was pur-
chased from Gibco. Charcoal-stripped fetal bovine serum,
naringenin and 4-OH-tamoxifen were from Sigma Aldrich.
Antibodies for ERK1/2, p-ERK1/2, AKT, p-AKT, caspase 7,
PARP and U0126 were obtained from Cell Signaling. Guava
Via-Count Reagent was purchased from Millipore. Actin
antibody was obtained from Abcam. Anti-ERa antibody (HC-
20) was from Santa Cruz biotechnology. AlexaFluor 488
conjugated Goat anti-Rabbit secondary antibody was obtained
from Jackson ImmunoResearch. Anti-mouse and anti-rabbit
horseradish peroxidase conjugated secondary antibodies
were purchased from Sigma Aldrich. The enhanced chem-
iluminescence (ECL) detection kit was from BioExpress.2.2. Cell cultureTam-R cells were cultured in Phenol-red free Dulbecco's
Modified Eagle Medium (DMEM) supplemented with 10%
charcoal-stripped FBS, 0.01 mg/mL bovine insulin, and
100 U/mL penicillin/streptomycin. Tam-R cells were main-
tained by adding 100 nM of tamoxifen. Cells were maintained
at 37 C and 5% CO2. Media was replaced every two days
and cells were passaged at 80% confluency. Tam-R cells
(2.45  104/plate) in growth phase were plated and either
treated with DMSO (Cont) or 200 mM Nar or 10 mM U0126 or
a combination of the two for 24, 48 or 96 h, as indicated.2.3. ImmunoblottingProtein extracts were subjected to 10% SDS-PAGE and
then transferred to an Immobilon-P membrane. The membrane
was incubated with the specific primary and secondary anti-
bodies indicated and visualized using enhanced chem-
iluminescence (ECL) and a Bio-Rad ChemiDoc XRS. Protein
bands were quantified using densitometric analysis using
Quantity One analysis software.2.4. Flow cytometryMCF-7 cells were collected and centrifuged for 5 min at
low speed (5), and the pellet was resuspended in 1PBS.
Guava Via-Count Reagent was added to cells at a 1:20 or 1:10
dilution and incubated for five min at room temperature in the
dark. Guava easy-Cyte Flow Cytometry was used to determine
the percentage of viable, mid-apoptotic, and dead cells. Values
were analyzed by guavaSoft software.
66 L. Eanes, Y.M. Patel / Biochimie Open 3 (2016) 64e712.5. Confocal microscopyMCF-7 cells were grown on cover slips. Cells were washed
with 1PBS, fixed with 3.7% paraformaldehyde for 15 min
and then permeabilized for 5 min in Triton-X (0.25% in
1PBS). Cells were blocked in a 5% goat serum - 1% BSA -
1PBS solution for 15 min. Cells were then incubated with
anti-ERa antibody (1:100) for 1 h at room temperature,
washed and incubated with secondary antibodies for 45 min at
room temperature. Cells were then stained with DAPI for
5 min. Cells were viewed by confocal microscopy.2.6. Quantification of ERa distributionERa levels were quantified by measuring the intensity of
fluorescence in both the cytoplasm and the nucleus. The
relative intensity was quantified using Image-Pro Plus soft-
ware (Silver Spring, MD). Briefly, intensities of nuclear and
cytoplasmic signals were measured and the ratio of the nu-
clear/cytoplasmic signal was averaged for individual cells
(n ¼ 5) for each treatment. A percent change formula,
[(Treatment e Vehicle)/(Vehicle) x 100%], was used to
determine change in protein localization.2.7. Statistical analysisData presented as means ± SEM. The significance of
comparing means was assessed by two-way analysis of Stu-
dent's t-test (StatPlus, AnalystSoft).
3. Results3.1. Naringenin does not alter ERa expressionPrevious studies have shown that the optimal concentration
of Nar required to significantly impair cell proliferation and
cell viability is 100e200 mM in MCF-7 breast cancer cells
[23]. Furthermore, it is known that MCF-7 cells are ERa
positive, and require the ER for cell growth. To determine if
the concentration of Nar administered in this study is alteringFig. 1. Nar does not impair ERa levels. Tam-R MCF-7 cells were grown in charco
(200 mM) for 24, 48, and 96 h. (A) Protein lysates were subjected to SDS-PAGE an
quantified using densitometric analysis by Quantity One Software and expressed a
iments. Results were the means ± SEM of three independent experiments. *p < 0the expression of ERa in Nar treated MCF-7 Tam-R cells, we
treated cells with or without Nar for 24, 48, and 96 h. The
protein levels of ERa were normalized to the levels present in
vehicle control cells. Our findings revealed no significant
difference in the expression of ERa in Nar treated cells
compared to the vehicle control at all three time points
(Fig. 1). Relatively low levels of the ER in Tam-R MCF-7 cells
can be expected due to the decreased dependence on estrogen
for growth as a result of increased signaling for alternative
proliferation pathways.3.2. Naringenin is a weak ERK1/2 inhibitorPrevious studies have shown that Nar inhibits cell prolif-
eration as a result of decreased cell viability [24e26]. We have
shown that Nar decreased ERK1/2 protein levels and relo-
calized ERa to a peri-nuclear region of the cell. These findings
suggest that Nar's effects on cell proliferation, viability, and
ERa localization could be a result of inhibition of ERK1/2.
We wanted to determine if the inhibition of ERK1/2 could
account for all of Nar's effects on Tam-R MCF-7 breast cancer
cells. We compared the effects of Nar to that of U0126, a
known inhibitor of MEK and thus phosphorylation of ERK1/2.
First we wanted to determine if U0126 elicits the same effects
as Nar on ERK1/2, so we treated Tam-R cells with Nar,
U0126, and a combination of the two for 24, 48, and 96 h
(Fig. 2). The protein levels (Fig. 2A and C) and phosphory-
lation status of ERK1/2 (Fig. 2A and B) were assayed using
immunoblot analysis and normalized to vehicle treated Tam-R
MCF-7 cells. Our findings confirmed that Nar is an inhibitor of
ERK1/2 phosphorylation (Fig. 2A). However, when compared
to the U0126 treatment, Nar appears to be a weak inhibitor of
ERK1/2 phosphorylation (Fig. 2A). Phosphorylated ERK1/2
was either undetectable (24 h) or extremely low (48 and 96 h)
in the U0126 alone and the combination treatment (Fig. 2A
and B). In contrast, Nar treatment only resulted in a 50% in-
hibition of ERK1/2 phosphorylation. Lastly, all three treat-
ments showed a decrease in the total levels of ERK after 96 h
of treatment when compared to the vehicle control. However,
the observed decrease is greater in the U0126 alone andal-stripped medium with 4-OHT (100 nM) in the presence or absence of Nar
d immunoblotted using antibodies against ERa and actin. (B) ERa to actin was
s a percent of the control. The results are representative of 3 separate exper-
.05.
Fig. 2. Nar is a weak inhibitor of ERK1/2 phosphorylation. Tam-R MCF-7 cells were grown in charcoal-stripped medium with 4-OHT (100 nM) in the presence of
Nar (200 mM), U0126 (10 mM) or a combination of the two for 24, 48, and 96 h. (A) Protein lysates were subjected to SDS-PAGE and immunoblotted using
antibodies against phospho-ERK1/2, ERK1/2 and actin. (B) P-ERK to actin and (C) ERK to actin were quantified using densitometric analysis by Quantity One
software and are expressed as a percent of the control. The results are representative of 3 separate experiments. *p < 0.05.
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treatment reduced the levels of ERK1/2, U0126 was more
effective at lowering the levels.3.3. Inhibition of ERK1/2 alone does not account for the
decreased viability seen in Nar treated cellsOur previous studies have shown that Nar decreased cell
proliferation [22,27,28]. This decrease in cell proliferation
may be in part attributed to the observed inhibition on ERK1/2Fig. 3. Inhibition of ERK alone cannot explain Nar decreased cell viability. Tam-R M
the presence of Nar (200 mM), U0126 (10 mM) or a combination of the two for 24
Results are the means ± SEM of three separate experiments. Data were normalized
means ± SEM of three independent experiments. Data were normalized to controlevels. We wanted to determine if inhibition of ERK1/2 alone
results in decreased cell proliferation to the same extent as
Nar. We treated Tam-R cells as previously stated with Nar,
U0126, or a combination of the two and assayed cell prolif-
eration (Fig. 3). Cell densities (cells/mL) from each treatment
were analyzed by flow cytometry (Fig. 3A). There was no
significant difference in cell density in any of the treatment
groups after 24 and 48 h when compared to the vehicle con-
trol. However, after 96 h of treatment all three groups showed
a decrease in cell density. Both U0126 and Nar appear to elicitCF-7 cells were grown in charcoal-stripped medium with 4-OHT (100 nM) in
, 48, or 96 h. (A) Cell density (cells/mL) was determined by flow cytometry.
to control. (B) Cell viability was determined by flow cytometry. Results are the
l. *p < 0.05.
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been shown to decrease cell proliferation as a result of
decreased cell viability we wanted to determine if the effects
on cell viability are a result of Nar targeting and inhibiting
ERK1/2 (31). Cell viability analysis revealed that both Nar
and U0126 reduced viability in 96 h to the same extent
(Fig. 3B). However, when U0126 and Nar were used in
combination there appears to be an additive effect resulting in
a greater decrease in cell viability (Fig. 3B).3.4. Nar induces apoptosisPrevious studies reported that Nar induced apoptosis
through PARP and caspase activation in HeLa and MCF-
7 cells [14,21]. We have shown that Nar can induce apoptosis
through the activation of caspase 7, which may explain the
observed decrease in cell viability. In order to determine if
induced apoptosis in Nar treated cells is a result of ERK1/2
inhibition we examined the levels of apoptotic cells and the
status of known apoptotic markers in U0126 treated cells. We
treated Tam-R MCF-7 cells with Nar, U0126, or a combina-
tion of the two and determined the number of apoptotic cells to
determine if the observed decrease in cell viability and
apoptosis correlated and whether inhibition of ERK1/2 alone
was responsible for the effects of Nar on viability. Our findings
show that there was an increase in apoptotic cells in allFig. 4. Nar and U0126 induce apoptosis. Tam-R MCF-7 cells were grown in charc
U0126 (10 mM) or a combination of the two for 24, 48, or 96 h. (A) Apoptotic cel
independent experiments. Data were normalized to control. (B) Protein lysates were
7, PARP, and actin. (C) Caspase 7 and (D) PARP were quantified using densitomet
control. Results are the means ± SEM of three separate experiments. Results aretreatment groups when compared to the control at each time
point (Fig. 4A). Our data also indicated that there was no
significant difference between the treatment groups over time.
Our data for apoptotic cells correlated with the decrease in cell
viability.
To determine the mechanism of apoptosis we assayed
known apoptotic markers, caspase 7 and PARP, in Nar and
U0126 treated Tam-R cells. Our results indicate that both Nar
and U0126 lead to the activation of caspase 7 and the
cleavage of PARP (Fig. 4B). After 24 h all three treatments
showed a decrease in full-length caspase 7 expression. Nar
maintains an approximate 20% decrease in caspase 7 at all
three time points (Fig. 4C). The combination treatment and
U0126 alone show an almost complete activation of caspase
7 at 96 h (Fig. 4B and C). The combination treatment shows a
greater effect than Nar or U0126 alone at 48 h and 4 days
(Fig. 4B and C).
Next we examined the expression of full-length PARP, a
downstream target of caspase 7. Quantified data for PARP
revealed that all three treatments decreased PARP expression
(Fig. 4B and D). Nar resulted in a 10e30% decrease in PARP
while U0126 resulted in an approximate 30% decrease at all
three time points when compared to the control. The combi-
nation treatment shows an approximately 40e50% decrease
across all time points when compared to the control. Similar to
the flow cytometry findings, the caspase and PARP analysisoal-stripped medium with 4-OHT (100 nM) in the presence of Nar (200 mM),
ls were determined by flow cytometry. Results are the means ± SEM of three
subjected to SDS-PAGE and immunoblotted using antibodies against Caspase
ric analysis using Quantity One software and are expressed as a percent of the
normalized to control. *p < 0.05.
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than either Nar or U0126 alone when compared to the control.3.5. Nar alone influences ERa localizationNext we examined the localization pattern of ERa. ER is
found in both the cytoplasm and nucleus [11,29e31]. ERa
enters the nucleus after either estrogen binding or phosphor-
ylation [10e13,16]. We have shown that Nar localizes ERa to
a peri-nuclear region of the cell. To determine if the effect of
Nar on ERa localization was a result of Nar inhibiting ERK1/2
we treated cells with Nar, U0126 or a combination of the two
as previously stated and performed confocal microscopy as
described in Material and Methods (Fig. 5A and B). Similar to
previous studies, our results show that the vehicle treated Tam-
R MCF-7 have an even distribution of ERa in the cytoplasm
and nucleus in all three time points (Fig. 5B). ERa and DAPI
were imaged at all time points and a representative image of
the 96 h time point is shown in Fig. 5A, U0126 treated cells
also show an even distribution of ERa at all the time points
with no difference when compared to the control (Fig. 5A. gei
and B). In contrast, cells treated with Nar and the combination
treatment exhibited only 20e30% of ERa within the nucleus.
ERa was localized primarily to a peri-nuclear region of the
cell at all three time points (Fig. 5A. def; jel and B). These
findings suggest that the inhibition of ERK1/2 by Nar is not
responsible for the observed changes in ERa localization.
4. Discussion
Tam is the most widely used ER antagonist employed to
treat ERþ breast cancers [2,4]. While ERa bound by Tam can
still translocate into the nucleus it is unable to recruit the co-
activators required for transcription. Unfortunately, the long
term use of Tam, results in resistance [2,4]. Tam-R cells
overcome the effects of Tam and achieve ERa activation
through kinase signaling pathways such as the MAPK
pathway [7,8]. It has been shown that Nar can inhibit theFig. 5. ERK1/2 does not regulate ERa localization. Tam-R MCF-7 cells were grow
(200 mM), U0126 (10 mM) or a combination of the two for 24, 48, and 96 h. (A) C
then subjected to confocal microscopy. (B) ERa localization data was quantified us
means ± SEM of three separate experiments. Results are normalized to control. *MAPK signaling pathway and interact with ER [30,31]. The
effects of Nar and other flavanones have been studied in
relation to glucose uptake, as endocrine disruptors as well as
their use as a possible therapeutics in multiple cancers
[11,22,24,30]. However, the specific mechanism(s) responsible
for the effects of Nar are unknown.
Since Nar treatment has been shown to alter ERK and ERK
is known to be involved in cell proliferation and survival, we
wanted to determine if the cytotoxic effects observed with Nar
could be attributed to the inhibition of ERK. Our studies
suggest that all of the effects observed in Nar treated Tam-R
cells cannot be fully explained by the inhibition of ERK1/2.
Although our data show that both Nar and U0126 decrease cell
viability and induce apoptosis to a similar extent, when used in
combination there is a greater decrease that appears to be
additive. The additive effect of Nar and U0126 on cell viability
is present at both 48 and 96 h of treatment and correlates with
the increased apoptosis seen at these time points in the com-
bination treatments. These results suggest that while Nar does
target ERK it also targets other proteins involved in cell
viability and apoptosis. Our results do not show a significant
change in cell density (approximate 50% decrease) at 30 h as
shown in previous reports [14]. However, this difference could
be a result of our studies using Tam-R MCF-7 cells compared
to MCF-7 cells used in other previous studies.
Furthermore, our studies show that Nar is a weaker inhib-
itor of ERK1/2 phosphorylation and protein levels than
U0126. Our results showed a 40e50% decrease in phosphor-
ylated ERK1/2 in Nar treated cells which is comparable to
previous studies using MCF-7 breast cancer cells [30]. Our
data suggests that Nar and U0126 could be eliciting these
effects through different mechanisms or that Nar may interact
with different target proteins. Nar could be targeting proteins
upstream of MEK or other proteins involved in the regulation
of the MAPK pathway. This could explain our observed ad-
ditive effect in the combination treatments.
Since previous studies have shown that Nar interacts with
the ER, albeit weakly and that Nar changes the localizationn in charcoal-stripped medium with 4-OHT (100 nM) in the presence of Nar
ells (96 h time point) were fixed and stained with ERa antibody and DAPI and
ing intensity parameters as described in Method and Materials. Results are the
p < 0.05.
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this change through direct inhibition of ERK. While neither
Nar treatment nor U0126 altered the total protein levels of
ERa in Tam-R MCF-7 breast cancer cells, only Nar altered the
localization pattern of ERa when compared to untreated Tam-
R cells. Cells treated with U0126 did not alter the ER local-
ization pattern when compared to the untreated cells. These
data suggest that Nar could be directly interacting with the ER
to localize ER to a peri-nuclear region or it could be targeting
proteins involved in ER localization and regulation. If Nar is
binding to ERa then our studies would be the first to suggest
that a NareERa complex was either prevented from entering
the nucleus or that the complex was actively transported out of
the nucleus. Further studies are needed to determine the
mechanism of action of Nar on ERa localization. This effect is
specific to Nar and cannot be explained by inhibiting ERK1/2
protein levels and/or phosphorylation.
Furthermore, our studies show that even in the absence of
estrogen, Nar is still able to inhibit ERK1/2 phosphorylation
and change ERa localization. Previous studies suggested that
the ER could activate the MAPK pathway and in turn ERK
could activate the ER. By inhibiting ERK with U0126 or Nar
the ER should not be activated by phosphorylation and thus
remain inactive. Either the ER is activated by other signaling
pathways or is bypassed altogether. This may suggest that Nar
affects signaling pathways other than those dependent on es-
trogen and thus may be targeting multiple proteins.
5. Conclusion
While the use of natural compounds to treat various dis-
orders is being explored, it is critical to determine the under-
lying molecular and cellular mechanisms of these compounds
in order to determine efficacy. To investigate the mechanism of
action of Nar, we examined the contribution of one of the main
targets of Nar, ERK. More specifically, we wanted to deter-
mine if inhibition of ERK alone mediated all the effects of Nar
on cell proliferation and viability in Tam-R MCF-7 breast
cancer cells. Our studies demonstrated that Nar and ERK in-
hibition impaired proliferation and viability, but the combi-
nation resulted in greater inhibition than either compound
alone suggesting that Nar may have other targets Surprisingly,
ERK was not involved in the peri-nuclear re-localization of
ERa seen in Nar treated Tam-R cells. Taken together, these
studies suggest that Nar targets multiple proteins to elicit its
effects on cell proliferation and survival.
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